A June FDA advisory committee will be a huge moment for struggling bluebird bio. A positive decision by FDA coupled with the favorable ICER assessment could lead to a robust cash flow. Being considered cost-effective may offer Zynteglo a distinct advantage in its negotiations with payers.
ICER’s Favorable Assessment Of Bluebird Bio’s Gene Therapy Zynteglo May Have Important Pricing And Reimbursement Implications
